At a glance
ClinicalIndex Comparison RecordPhase 2Active· 27 enrolled
Drug / intervention
Osimertinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Osimertinib and Therapeutic Conventional Surgery for Stage I Non-Small Cell Lung Cancer and 6 related conditions. Active but no longer recruiting, targeting 27 participants across 3 sites.
Detailed Summary
This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery. Osimertinib may stop the growth of tumor cells by blocking mutant EGFR signaling in cancer cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2Active
20182019202020212022202320242025202620272028
First PostedFeb 2018
Enrollment StartJul 2018
Primary CompletionJan 2023
TodayJul 2026
Study CompletionSep 2027
First PostedFeb 14, 2018
Enrollment StartJul 31, 2018
Primary CompletionJan 31, 2023
Study CompletionSep 30, 2027
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 8.4 years ago
Interventions
Osimertinibdrug
Given PO (orally)
Therapeutic Conventional Surgeryprocedure
Undergo surgery